Avidity Biosciences, Inc.
RNAM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RNAM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 12 clinical trials · 1 catalyst for Avidity Biosciences, Inc..
Run Avidity Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avidity Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
14.3 months
D/E 0.16
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~2d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Frequently asked questions
What is Avidity Biosciences, Inc.'s next catalyst?
Avidity Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Sa" — expected September 1, 2026.
Who is the CEO of Avidity Biosciences, Inc.?
Ms. Sarah Boyce is the chief executive officer of Avidity Biosciences, Inc. (RNAM).
Where is Avidity Biosciences, Inc. headquartered?
Avidity Biosciences, Inc. (RNAM) is headquartered in San Diego, CA, United States.
What therapeutic areas does Avidity Biosciences, Inc. focus on?
Avidity Biosciences, Inc. develops therapies across Rare Disease, Neurology, Cardiovascular, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.